Im­muno­Gen’s ovar­i­an can­cer come­back not as rosy as ex­pect­ed as pro­gres­sion-free sur­vival lags

Back in No­vem­ber, Im­muno­Gen ral­lied in­vestors with what looked like a come-from-be­hind Phase III win. But this morn­ing, the biotech was back to play­ing de­fense …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER